0001127602-23-014612.txt : 20230504 0001127602-23-014612.hdr.sgml : 20230504 20230504203224 ACCESSION NUMBER: 0001127602-23-014612 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230502 FILED AS OF DATE: 20230504 DATE AS OF CHANGE: 20230504 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: REESE DAVID M CENTRAL INDEX KEY: 0001748434 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 23890768 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 4 1 form4.xml PRIMARY DOCUMENT X0407 4 2023-05-02 0000318154 AMGEN INC AMGN 0001748434 REESE DAVID M ONE AMGEN CENTER DRIVE THOUSAND OAKS 1 EVP, Research and Development 0 Common Stock 2023-05-02 4 A 0 3814 0 A 55527 D Common Stock 2023-05-03 4 F 0 819 235.97 D 54708 D Nqso (Right to Buy) 235.97 2023-05-02 4 A 0 32250 0 A 2025-05-02 2033-05-02 Common Stock 32250 32250 D The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. These shares include the following RSUs granted under the Company's equity plans: 2,325 RSUs which will vest in installments of 1,145 on 5/5/2023 and 1,180 on 5/5/2024; 2,685 RSUs which will vest in installments of 1,322 on 4/30/2024 and 1,363 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026, and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. These shares include 528 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively. /s/ David M. Reese 2023-05-03